

          1. Patients with other diseases that may affect, in the opinion of study researchers, the
             implementation of the study or the observation of the efficacy data;

          2. Patients with severe Coronavirus Disease 2019 (COVID-19), that is based on "Guidance
             of Diagnosis and Treatment for Patients with Coronavirus Disease 2019 (COVID-19)
             (Procedural Version 5 Amendment)" with respect to the criteria for clinical severity
             classification;

          3. Female patients with known pregnancy and in lactation at screening;

          4. Patients with previous allergies to T89 or Radix Salvia Miltiorrhizae, Radix
             Notoginseng and Borneol;

          5. Any other condition that, in the opinion of the investigator, may affect the conduct
             of the study, reduce compliance or increase the risk of patients.
      